Key result
Pimobendan added to standard therapy resulted in a longer mean survival time of 375 days compared to 265 days with hawthorn extract and 215 days with carvedilol in dogs with dilated cardiomyopathy.
Why the study?
The study was undertaken to evaluate the efficacy of carvedilol and hawthorn extract in managing dilated cardiomyopathy to limit treatment costs and improve pet quality of life.
Does carvedilol or hawthorn extract improve left ventricular contractility and survival compared to pimobendan in dogs with dilated cardiomyopathy?
RCT (n=30)
Randomly allotted
No
Does carvedilol or hawthorn extract improve left ventricular contractility and survival compared to pimobendan in dogs with dilated cardiomyopathy?
Answers are grounded in this paper and cite their sources.
Pimobendan is superior to carvedilol and hawthorn extract in improving left ventricular contractility and survival in dogs with dilated cardiomyopathy, though hawthorn extract offers a moderate benefit.
The present study was undertaken to evaluate the effect of carvedilol and hawthorn extract in managing dilated cardiomyopathy (DCM) to limit the treatment cost and improve the quality of pet life. Total 165 dogs were subjected to detailed clinical and physical examination, electrocardiography and echocardiography. Out of 165 dogs, 61(36.96%) were diagnosed as DCM, out of which 30 were allocated randomly to three treatment groups comprising ten dogs in each group. Group-I dogs were treated with pimobendan, digoxin, enalapril and furosemide. In Group-II and III, pimobendan was replaced with carvedilol and hawthorn extract, respectively. Dogs with ventricular arrhythmias (Ventricular Premature Complexes, Ventricular fibrillation) were excluded from the treatment groups as digoxin is contraindicated in ventricular arrhythmias. A noticeable improvement in clinical signs, thoracic radiographic findings, left ventricular dimensions and left ventricular contractility indices was observed in the three treatment groups after 28 days of treatment when compared to the pre-treatment values. The drug's therapeutic efficacy was evaluated based on comparative assessment of post treatment left ventricular contractility indices (fractional shortening and ejection fraction). Group I had longer survival time with mean of 375 ± 14.25 days followed by Group III (264.67 ± 41.22 days) and Group II (214.57 ± 31.32 days) dogs.
No takes yet. Share an insight, caveat, or question.
K. et al. (2022) conducted an RCT in Dilated Cardiomyopathy (n=30). Carvedilol or Hawthorn extract vs. Pimobendan 0.25 mg/kg bid was evaluated on Mean survival time (days). Pimobendan added to standard therapy resulted in a longer mean survival time of 375 days compared to 265 days with hawthorn extract and 215 days with carvedilol in dogs with dilated cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: